vs
Journey Medical Corp（DERM）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
ROCKWELL MEDICAL, INC.的季度营收约是Journey Medical Corp的1.1倍（$17.3M vs $16.1M），Journey Medical Corp净利率更高（-7.8% vs -9.2%，领先1.5%），Journey Medical Corp同比增速更快（27.3% vs -8.5%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs -18.2%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
DERM vs RMTI — 直观对比
营收规模更大
RMTI
是对方的1.1倍
$16.1M
营收增速更快
DERM
高出35.8%
-8.5%
净利率更高
DERM
高出1.5%
-9.2%
两年增速更快
DERM
近两年复合增速
-18.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $17.3M |
| 净利润 | $-1.2M | $-1.6M |
| 毛利率 | — | 16.8% |
| 营业利润率 | -2.8% | — |
| 净利率 | -7.8% | -9.2% |
| 营收同比 | 27.3% | -8.5% |
| 净利润同比 | -182.0% | — |
| 每股收益（稀释后） | $-0.04 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRMTI
| Q1 26 | — | $17.3M | ||
| Q4 25 | $16.1M | $18.3M | ||
| Q3 25 | $17.0M | $15.9M | ||
| Q2 25 | $15.0M | $16.1M | ||
| Q1 25 | $13.1M | $18.9M | ||
| Q4 24 | $12.6M | $24.7M | ||
| Q3 24 | $14.6M | $28.3M | ||
| Q2 24 | $14.9M | $25.8M |
净利润DERMRMTI
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $-1.2M | $-554.0K | ||
| Q3 25 | $-2.3M | $-1.8M | ||
| Q2 25 | $-3.8M | $-1.5M | ||
| Q1 25 | $-4.1M | $-1.5M | ||
| Q4 24 | $1.5M | $-756.0K | ||
| Q3 24 | $-2.4M | $1.7M | ||
| Q2 24 | $-3.4M | $343.0K |
毛利率DERMRMTI
| Q1 26 | — | 16.8% | ||
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | 82.3% | 14.7% | ||
| Q3 24 | 63.9% | 22.0% | ||
| Q2 24 | 56.0% | 17.6% |
营业利润率DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | -2.2% | ||
| Q3 25 | -9.0% | -9.9% | ||
| Q2 25 | -19.2% | -8.4% | ||
| Q1 25 | -25.3% | -7.2% | ||
| Q4 24 | 17.7% | -2.1% | ||
| Q3 24 | -19.8% | 6.8% | ||
| Q2 24 | -19.7% | 2.0% |
净利率DERMRMTI
| Q1 26 | — | -9.2% | ||
| Q4 25 | -7.8% | -3.0% | ||
| Q3 25 | -13.6% | -11.0% | ||
| Q2 25 | -25.3% | -9.3% | ||
| Q1 25 | -31.0% | -8.0% | ||
| Q4 24 | 12.1% | -3.1% | ||
| Q3 24 | -16.3% | 5.9% | ||
| Q2 24 | -22.6% | 1.3% |
每股收益（稀释后）DERMRMTI
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $-0.04 | $-0.01 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.16 | $-0.05 | ||
| Q1 25 | $-0.18 | $-0.04 | ||
| Q4 24 | $0.10 | $-0.02 | ||
| Q3 24 | $-0.12 | $0.04 | ||
| Q2 24 | $-0.17 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | — |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $35.9M |
| 总资产 | $94.6M | $57.4M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | $24.1M | $10.7M | ||
| Q3 25 | $24.9M | $13.6M | ||
| Q2 25 | $20.3M | $12.5M | ||
| Q1 25 | $21.1M | $11.4M | ||
| Q4 24 | $20.3M | $15.7M | ||
| Q3 24 | $22.5M | $12.3M | ||
| Q2 24 | $23.9M | $11.9M |
总债务DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — |
股东权益DERMRMTI
| Q1 26 | — | $35.9M | ||
| Q4 25 | $31.9M | $37.0M | ||
| Q3 25 | $25.9M | $37.0M | ||
| Q2 25 | $19.2M | $30.4M | ||
| Q1 25 | $21.5M | $31.5M | ||
| Q4 24 | $20.1M | $32.6M | ||
| Q3 24 | $10.9M | $29.1M | ||
| Q2 24 | $11.3M | $23.5M |
总资产DERMRMTI
| Q1 26 | — | $57.4M | ||
| Q4 25 | $94.6M | $57.1M | ||
| Q3 25 | $85.2M | $57.5M | ||
| Q2 25 | $81.2M | $52.6M | ||
| Q1 25 | $85.0M | $54.0M | ||
| Q4 24 | $80.2M | $59.2M | ||
| Q3 24 | $64.0M | $57.1M | ||
| Q2 24 | $65.2M | $53.0M |
负债/权益比DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | $-6.3M | $2.3M | ||
| Q3 25 | $-2.4M | $-1.3M | ||
| Q2 25 | $-942.0K | $1.8M | ||
| Q1 25 | $-2.8M | $-3.5M | ||
| Q4 24 | $2.2M | $865.0K | ||
| Q3 24 | $-1.2M | $4.3M | ||
| Q2 24 | $-5.2M | $1.4M |
自由现金流DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M |
自由现金流率DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% |
资本支出强度DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% |
现金转化率DERMRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RMTI
暂无分部数据
